Novo Nordisk, Eli Lilly fall after Trump comments on weight loss drug pricing
Investing.com - Stifel has reiterated its Buy rating on Bausch & Lomb Corp. (NYSE:BLCO) while maintaining its $12.00 price target for the eye health company.
The research firm’s decision comes as Bausch & Lomb continues to navigate competitive challenges in several key market segments, including silicone hydrogel daily contact lenses, premium intraocular lenses, and dry eye treatments.
Stifel expressed particular concern about the company’s performance in the dry eye market, which it highlighted as a notable area where Bausch & Lomb faces execution challenges.
The firm also raised questions about Bausch & Lomb’s ability to achieve margin expansion over the longer term while competing effectively in these incremental markets.
Despite these concerns, Stifel maintained its positive outlook on the stock with the Buy rating, keeping its price target unchanged at $12.00 per share.
In other recent news, Bausch & Lomb Corp reported its second-quarter earnings for 2025, surpassing analyst expectations. The company achieved an earnings per share (EPS) of $0.07, exceeding the forecasted $0.06, marking a positive surprise of 16.67%. Additionally, Bausch & Lomb reported revenue of $1.29 billion, which surpassed the expected $1.26 billion. In another development, Goldman Sachs initiated coverage on Bausch & Lomb with a Neutral rating and set a price target of $16.00. The investment bank noted an ongoing business transition that could drive organic top-line growth by fiscal year 2026, supported by new product launches and a renewed commercial focus. These recent developments highlight the company’s performance and future potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.